MedWatch

ALK still has two horses in adrenaline race

ALK has two cards up its sleeve in its efforts to take shares of the adrenaline market. However, its in-house developed pen and partner Windgap's product may end up running heats for a spot in the final, as CEO Carsten Hellmann says they will "probably choose one at some point."

Carsten Hellmann, CEO of ALK | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

Allergy specialist firm ALK has still got two horses in the race to become the leading adrenaline pen distributor in the US.

Adrenaline pens are used to treat severe allergic reactions, also known as anaphylaxis, caused by allergies to things such as food substances or bee stings. In 2019, ALK, which is based in Copenhagen, entered into an alliance with Boston-based company Windgap, which is designing a next generation adrenaline pen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs